Please login to the form below

Not currently logged in
Email:
Password:

QuintilesIMS launches European oncology data-gathering initiative

Will collaborate with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer
QuintilesIMS

QuintilesIMS has teamed up with four big pharma firms to gather insights into the real-world use of oncology therapies across Europe.

Working with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer, the pharma services provider aims to bridge the gaps and inconsistencies in current data to generate a more comprehensive view of the sector.

Currently, treatment-use information in Europe is based on historical data and so only provides a backward-looking view of the area, according to the recently-merged QuintilesIMS.

Along with its partners QuintilesIMS wants to find out how oncology products are used in each country, by which patients, in which indications and in which combinations with other drugs, and so provide greater insight into current clinical practice.

It is hoped the project will generate more timely, consistent and complete data resources for pharma and, ultimately, enable healthcare providers to make better-informed decisions on patient care in future.

Cancer is the second-highest cause of death and morbidity in Europe, with over 1.7 million deaths and three million new diagnoses every year.

Article by
Rebecca Clifford

13th December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics